Menu

CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: November-11-16
Credit Expiration Date: November-11-17

Faculty

Nicola A. Hanania, MD, MS
Associate Professor of Medicine
Pulmonary and Critical Care Medicine
Director, Asthma Clinical Research Center
Baylor College of Medicine
Houston, TX

James F. Donohue, MD
Professor of Medicine
Division of Pulmonary and Critical Care Medicine
University of North Carolina at Chapel Hill
Chapel Hill, NC


CCME Reviewer:
David L. Rosenstreich, MD
Professor of Medicine, Microbiology & Immunology, and Otorhinolaryngology
Chief, Division of Allergy & Immunology
Albert Einstein College of Medicine and Montefiore Medical Center
Bronx, NY

 

Credit Hours

0.5 AMA PRA Category 1 Credit

Medium

Mobile + Online on QuantiaMD

Program Description

Severe asthma is a heterogeneous condition that consists of multiple phenotypes. Roughly 10% of individuals with asthma experience poor control because they suffer from an underlying severe asthma pathophysiology characterized by airway inflammation resistant to conventional therapy. This activity will examine treatments tailored to various phenotypes.

Program Developer/Facilitator


.

Target Audience

This educational activity is designed to meet the needs of allergists, pulmonologists, immunologists, internists, and other clinicians managing severe asthma.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Describe the mechanism of action of available and emerging biologic agents for severe asthma.
  2. Assess the clinical data on the safety and efficacy of available and emerging biologic agents for severe asthma.
  3. Identify which patients with severe asthma should be considered for biologic agents.

Disclosures

The “Conflict of Interest Disclosure Policies” of Albert Einstein College of Medicine require that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also require that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Contributors whose COIs are irresolvable are not permitted to participate in Einstein CME activities.
James F. Donohue, MD, discloses the following:
Consultant: GlaxoSmithKline, Boehringer Ingleheim, Novartis, AstraZeneca, Gilead

Nicola A. Hanania, MD, MS, discloses the following:
Consultant: AstraZeneca, Boehringer Ingleheim, Roche, Mylan, Novartis
Contracted Research: GlaxoSmithKline, Cheisi, Boehringer Ingleheim, Roche, Mylan, AstraZeneca

David L. Rosenstreich, MD, has no conflicts of interest to disclose.

The staff of CCME of Albert Einstein College of Medicine have no disclosures to report with any commercial interests relative to this CME activity.
Lillian McVey, Writer/Editor, MCM Education, has no conflicts of interest to disclose.
Kathleen Hines, Vice President, Editorial Services, MCM Education, has no conflicts of interest to disclose.
Terry Ann Glauser, MD, MPH, Vice President, Medical Affairs, MCM Education, has no conflicts of interest to disclose.

Credit Statements

This activity has been planned and implemented in accordance with the requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint providership of Albert Einstein College of Medicine, Montefiore Medical Center, and MCM Education. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Albert Einstein College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support Statements

This activity is supported by independent educational grants from Novartis Pharmaceuticals and AstraZeneca.

Instructions

Completion Instructions

  1. Accessing Activity:
    * Click "Start Program" and log into program on QuantiaMD.com
    * Take the pre-test
    * Review the activity
    * Take the post-test and score 80%
    * You are allowed a total of 3 attempts
    * Complete the evaluation
    * View, print, or save a CME certificate verifying your
    credit/participation in this activity
  2. Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers

Certificate Fee

$0.00

There is no charge for CME credit.

Disclaimer

© 2016 MCM Education. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Albert Einstein College of Medicine, Novartis Pharmaceuticals, or AstraZeneca. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu
EDITOR'S PICKS